AAS
CRNX icon

Ameritas Advisory Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ameritas Advisory Services’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-300
Closed -$8.63K – 2272
2025
Q2 		$8.63K Buy
+300
New +$9.27K ﹤0.01% 2072
2023
Q2 		– Sell
-300
Closed -$5.7K – 943
2023
Q1 		$5.7K Buy
+300
New +$5.55K ﹤0.01% 2112

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ameritas Advisory Services's CRNX Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 300 shares — an estimated $8.63K sold.

Ameritas Advisory Services first reported a position in CRNX in Q1 2023 and held it in 2 quarters. The position peaked at $8.63K in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 300 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $8.63K.
  • Ameritas Advisory Services first reported a position in Crinetics Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Ameritas Advisory Services's Crinetics Pharmaceuticals position peaked at $8.63K in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.